Current Approaches and Innovations in Managing Preeclampsia: Highlighting Maternal Health Disparities

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Public Health

Background:

• Preeclampsia (PE) is a significant global cause of maternal mortality and morbidity, impacting 3-6% of pregnancies.
• Characterized by new-onset hypertension and end-organ dysfunction after 20 weeks gestation, PE requires timely diagnosis and management.
• Black women face disproportionately higher risks due to factors including hypertension, healthcare disparities, and genetic predispositions like the APOL1 gene.

Purpose of the Study:

• To review current and emerging management strategies for preeclampsia.
• To explore the underlying causes of health disparities in PE, particularly for Black women.
• To propose solutions for improving preeclampsia outcomes and reducing maternal mortality.

Main Methods:

• Literature review of current clinical guidelines and emerging research on preeclampsia management.
• Analysis of factors contributing to health disparities in preeclampsia.
• Synthesis of evidence on novel therapeutic approaches and preventative measures.

Main Results:

• Current management focuses on early diagnosis, blood pressure control, and delivery.
• Low-dose aspirin and magnesium sulfate are established preventative and therapeutic agents.
• Emerging strategies include antiangiogenic therapies, HIF suppression, statins, and supplements like CoQ10.

Conclusions:

• Effective preeclampsia management requires a multi-faceted approach including established and novel therapies.
• Addressing healthcare disparities and genetic factors is crucial for improving outcomes, especially in high-risk populations.
• Further research into emerging treatments and health equity is essential for reducing the global burden of preeclampsia.